FDA Meeting Addresses Industry Concerns over New Fees Schedule - SPIK
FDA meets industry leaders to discuss new fees, reducing application costs and ensuring fair regulatory processes.
FDA fees, Administrative Order 2024-0016, industry concerns, regulatory updates, Philippines FDA, application fee adjustment
20125
post-template-default,single,single-post,postid-20125,single-format-standard,bridge-core-1.0.5,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,wpb-js-composer js-comp-ver-8.0,vc_responsive

20 Mar FDA Meeting Addresses Industry Concerns over New Fees Schedule

Posted at 09:50h in 2025 Events, SPIK News by
Spread the love

The Food and Drug Administration (FDA) recently held a significant meeting on March 20, 2025, chaired by Director General Dr. Samuel A. Zacate. The event saw the attendance of various representative associations, including the Samahan sa Pilipinas ng mga Industriyang Kimika (SPIK) represented by Director Mary Grace San Jose, the Federation of Indian Chamber of Commerce (Phils.), the Philippines Stationeries Associations, the Philippine Paint and Coatings Associations, and the Cosmetics, Toiletry, and Fragrance Associations of the Phils. 

The main agenda of the meeting was to discuss the issues and concerns related to the newly proposed FDA schedule of fees and charges, outlined in Administrative Order (AO) No. 2024-0016. The AO, which was published on December 28, 2024, following its approval on Dec 09, 2024, aims to address the sufficiency of fees and charges as mandated by Republic Act No. 9711 (Food and Drug Administration Act 2009) and Section 17 of Republic Act No. 9502 Chapter 4. The discussions focused on the breakdown of costs as per DOF-DBM-NEDA Joint Circular No. 1-2013 and the implementing rules and regulations of Administrative Order No. 31, S.2012.

Some key points discussed were the increase in the application fee from PHP 100 to PHP 1,000 and the subsequent decision to lower it to PHP 250 after considering the feedback from the industry stakeholders. Additionally, the FDA’s need to enhance the salaries of its assessors and undergo facility renovations was brought to the forefront. It was also agreed upon to establish regular monthly meetings similar to CICAC meetings of the Bureau of Customs (BOC), to maintain open dialogue and address any concerns promptly.

The meeting concluded with the assurance that the FDA would take all concerns into consideration and work towards a balanced approach that benefits both the industry and the public health sector. The proposal for a monthly meeting with the FDA was also well-received and is set to take place throughout the year to ensure a smoother implementation of the new fee structure. This collaborative step is expected to streamline processes and improve overall efficiency within the regulatory framework.